SCHEMBL9968844

SCHEMBL9968844

CCOC(=O)CN1C(=O)CC(Cc2ccc(O)cc2O)C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KMT2A Q03164 2/20 0.40
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
MEN1 O00255 1/20 0.40
RAB9A P51151 1/20 0.40
PIN1 Q13526 1/20 0.40
PIN4 Q9Y237 1/20 0.40
AKR1B1 P15121 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29392707 1.00 PPARG (0.45) PPARGL3MBTL1KMT2AGSK3AGSK3B
SCHEMBL9936606 0.87 TNF (0.43) PPARGL3MBTL1TSHRCA12CA1
SCHEMBL9968847 0.86 L3MBTL1 (0.41) PPARGL3MBTL1KMT2ATSHRMEN1
SCHEMBL29390952 0.86 L3MBTL1 (0.41) PPARGL3MBTL1KMT2ATSHRMEN1
SCHEMBL9938468 0.83 TSHR (0.56) L3MBTL1KMT2ATSHRMEN1USP2
SCHEMBL9937177 0.83 L3MBTL1 (0.40) L3MBTL1KMT2ATSHRMEN1HTT
SCHEMBL15328838 0.82 TSHR (0.43) L3MBTL1KMT2ATSHRMEN1RAB9A
SCHEMBL9938471 0.81 CYP19A1 (0.41) L3MBTL1KMT2AGAATSHRMEN1
SCHEMBL9968851 0.81 ALDH1A1 (0.41) L3MBTL1KMT2AGAATSHRMEN1
SCHEMBL15341257 0.81 TYR (0.40) L3MBTL1KMT2ATSHRMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3393603-B1 TOPICAL DELIVERY SYSTEM FOR ACTIVE INGREDIENTS OREAL (FR) 2023-01-18 EP disclosed
US-11154473-B2 Composition comprising resorcinol or derivative thereof L'OREAL (FR) 2021-10-26 US disclosed
WO-2017110151-A1 TOPICAL DELIVERY SYSTEM FOR ACTIVE INGREDIENTS L'OREAL (FR) 2017-06-29 WO disclosed
US-20170087064-A1 COMPOSITION IN THE FORM OF NANO OR MICRO EMULSION OR WITH LAMELLAR STRUCTURE L'OREAL (FR) 2017-03-30 US disclosed
US-20170087064-A1 COMPOSITION IN THE FORM OF NANO OR MICRO EMULSION OR WITH LAMELLAR STRUCTURE L'OREAL (FR) 2017-03-30 US disclosed
WO-2015198922-A1 COMPOSITION IN THE FORM OF NANO OR MICRO EMULSION OR WITH LAMELLAR STRUCTURE L'OREAL (FR) 2015-12-30 WO disclosed
EP-2651886-B1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES ORÉAL L (FR) 2015-03-04 EP disclosed
US-8937187-B2 Method for depigmenting keratin materials using resorcinol derivatives L'OREAL (FR) 2015-01-20 US disclosed
US-8937187-B2 Method for depigmenting keratin materials using resorcinol derivatives L'OREAL (FR) 2015-01-20 US disclosed
US-20130281507-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES L'OREAL (FR) 2013-10-24 US disclosed
US-20130281507-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES L'OREAL (FR) 2013-10-24 US disclosed
WO-2012079938-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES L'OREAL (FR) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154473-B2 Composition comprising resorcinol or derivative thereof NQO1, LRAT, RBP4 PPARG 396/4885L3MBTL1 3046/4885KMT2A 1778/4885
US-20130281507-A1 METHOD FOR DEPIGMENTING KERATIN MATERIALS USING RESORCINOL DERIVATIVES KRT18, KLHL20, IK PPARG 4187/4885L3MBTL1 4589/4885KMT2A 144/4885
US-20170087064-A1 COMPOSITION IN THE FORM OF NANO OR MICRO EMULSION OR WITH LAMELLAR STRUCTURE LRAT, LIPA, DAGLA PPARG 375/4885L3MBTL1 3662/4885KMT2A 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.